Skip to content
VD

Venmax Drugs & Pharmaceuticals

531015 BSE
₹14.28

Close ·

P/E
57.12
View as Markdown
MCP
Close 4 Nov 2026 ₹14.28 −13.56 −48.7% 1Y
Start ₹27.84

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare

Price-based figures at the close · EPS basis: Standalone · TTM

ROCE
2.96%
Debt to Equity
0.02
EPS (TTM)
₹0.25
Book Value
₹14.37
Market Cap
—
P/E (TTM)
57.12
P/B
0.99
ROE
2.70%
Dividend Yield
0.00%
EBITDA
₹30.00 L
52W High
₹31.49
52W Low
₹12.51

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

38 Weak

Data confidence 95/100

Category scores

Quality
21
Poor
Returns, margins, earnings quality 22% weight
Valuation
24
Poor
Cheap vs sector & own history 24% weight
Growth
99
Strong
Sales & profit trajectory 9% weight
Financial Health
82
Strong
Solvency, leverage, coverage 9% weight
Momentum
8
Poor
Trend strength, vol-adjusted 12% weight
Ownership
50
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

3
  • Company is almost debt free.
  • Stock is trading at 1.12 times its book value
  • Debtor days have improved from 247 to 65.1 days.

Weaknesses

2
  • Promoter holding has decreased over last quarter: -3.34%
  • Promoter holding is low: 10.5%

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallBearish964
OscillatorsBearish360
Moving AveragesStrong Bearish604

Key readings

RSI (14)
50.22
Neutral
MACD (12,26,9)
−0.34
Bearish
SMA (50)
14.60
Bearish
SMA (200)
20.59
Bearish

As of

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y+15.31%
5Y+116.14%
3YZero base
1Y+890.12%
TTM+386.39%

Net profit

Net profit growth by window
10YTurned to profit
5YTurned to profit
3Y+2.82%
1YTurned to profit
TTMTiny base

Operating cash flow

Operating cash flow growth by window
10YOutflow widened by ₹10.81 Cr
5YTurned negative
3YTurned negative
1YOutflow widened by ₹8.71 Cr
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y+8.75 pp
5Y+195.62 pp
3YNo sales
1Y+132.36 pp
TTM+53.55 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹0.26 Cr
Mar 2018₹0.00 Cr
Mar 2019₹0.15 Cr
Mar 2020₹0.47 Cr
Mar 2021₹0.17 Cr
Mar 2022₹0.00 Cr
Mar 2023₹0.00 Cr
Mar 2024₹0.00 Cr
Mar 2025₹0.81 Cr
Mar 2026₹8.02 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017−₹1.34 Cr
Mar 2018−₹0.24 Cr
Mar 2019−₹0.24 Cr
Mar 2020−₹0.27 Cr
Mar 2021−₹0.16 Cr
Mar 2022₹1.85 Cr
Mar 2023₹0.23 Cr
Mar 2024₹0.06 Cr
Mar 2025−₹0.01 Cr
Mar 2026₹0.25 Cr

Quarterly Results

₹ Cr
531015 quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
0
0
0
0
0.1
0.17
0.2
0.33
1.21
1.32
1.55
3.94
2.48
Expenses
0.03
0.03
0.01
0.04
0.12
0.47
0.69
0.57
1.17
1.27
1.58
3.92
2.36
Operating Profit
−0.03
−0.03
−0.01
−0.04
−0.02
−0.3
−0.49
−0.24
0.04
0.05
−0.03
0.02
0.12
OPM %
—
—
—
—
−20%
−176.47%
−245%
−72.73%
3.31%
3.79%
−1.94%
0.51%
4.84%
Other Income
0.05
0
0.05
0.1
0.03
0
0
1.02
0
0
0.07
0.09
0
Interest
0
0
0
0
0
0
0
0
0
0
0
0
0
Depreciation
0
0
0
0
0
0
0
0
0
0
0
0
0
PBT
0.02
−0.03
0.04
0.06
0.01
−0.3
−0.49
0.78
0.04
0.05
0.04
0.11
0.12
Tax %
0%
0%
25%
16.67%
0%
0%
0%
0%
0%
40%
25%
0%
0%
Net Profit
0.02
−0.03
0.03
0.05
0.01
−0.3
−0.5
0.78
0.04
0.02
0.03
0.11
0.12
EPS (₹)
0.04
−0.06
0.06
0.1
0.02
−0.57
−0.95
1.49
0.08
0.02
0.04
0.09
0.1

Profit & Loss

₹ Cr
531015 profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
2.43
1.93
0.26
0
0.15
0.47
0.17
0
0
0
0.81
8.02
9.29
Expenses
2.54
2.07
0.88
0.23
0.38
0.72
0.5
0.12
0.19
0.11
1.87
7.9
9.13
Operating Profit
−0.11
−0.14
−0.62
−0.23
−0.23
−0.25
−0.33
−0.12
−0.19
−0.11
−1.06
0.12
0.16
OPM %
−4.53%
−7.25%
−238.46%
—
−153.33%
−53.19%
−194.12%
—
—
—
−130.86%
1.5%
1.72%
Other Income
0
0
−0.72
0
0
0
0.18
1.98
0.42
0.2
1.05
0.16
0.16
Interest
0
0
0
0.01
0
0
0
0
0
0
0
0
0
Depreciation
0
0
0
0
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0
0
PBT
−0.11
−0.14
−1.34
−0.24
−0.24
−0.26
−0.16
1.85
0.22
0.08
−0.02
0.28
0.32
Tax %
−36.36%
0%
0%
0%
0%
3.85%
0%
0%
0%
25%
0%
10.71%
—
Net Profit
−0.08
−0.14
−1.34
−0.24
−0.24
−0.27
−0.16
1.85
0.23
0.06
−0.01
0.25
0.28
EPS (₹)
−0.15
−0.27
−2.56
−0.46
−0.46
−0.52
−0.31
3.53
0.44
0.11
−0.02
0.22
0.25
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
—

Balance Sheet

₹ Cr
531015 balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
5.24
5.24
5.24
5.24
5.24
5.24
5.24
5.24
5.24
5.24
5.24
11.58
Reserves
−4.9
−5.04
−7.11
−7.35
−7.59
−7.86
−8.03
−6.18
−5.95
−5.89
−0.83
2.53
Borrowings
1.5
1.72
1.85
2.04
2.24
2.52
2.33
0.35
0.35
0.35
0.05
0.33
Other Liabilities
1.85
0.68
0.16
0.14
0.44
0.56
0.76
0.8
0.57
0.38
0.71
1.76
Total Liabilities
3.69
2.6
0.14
0.07
0.33
0.46
0.3
0.21
0.21
0.08
5.17
16.2
Fixed Assets
0
0
0
0
0.11
0.1
0.09
0.08
0.07
0.07
0.04
0.04
CWIP
0
0
0
0
0
0
0
0
0
0
0
0
Investments
0.01
0.01
0
0
0
0
0
0
0
0
0
0
Other Assets
3.68
2.59
0.14
0.07
0.22
0.36
0.21
0.13
0.14
0.01
5.13
16.16
Total Assets
3.69
2.6
0.14
0.07
0.33
0.46
0.3
0.21
0.21
0.08
5.17
16.2

Cash Flow

₹ Cr
531015 cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
−0.1
−0.19
−1.06
−0.26
−0.05
−0.28
0.26
1.91
0
0
−2.29
−11
Investing
0
0
0.01
0
−0.11
0
0
0
0
0
0
0
Financing
0.1
0.22
1.02
0.26
0.16
0.28
−0.19
−1.98
0
0
4.77
9.74
Net Cash Flow
0
0.03
−0.03
0
0
0
0.07
−0.07
0
0
2.48
−1.26
Free Cash Flow
−0.1
−0.19
−1.05
−0.26
−0.17
−0.28
0.26
1.91
0
0
−2.29
−11
CFO/OP
127
136
171
113
22
112
−79
−1,592
0
−18
216
−9,142

Ratios

531015 financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
21.03
129
0
—
0
31.06
85.88
—
—
—
428
65.08
Inventory Days
225
0
0
—
446
251
0
—
—
—
27.72
50.14
Days Payable
252
—
—
—
1,257
456
—
—
—
—
291
84.23
Cash Conversion Cycle
−5.04
129
0
—
−811
−174
85.88
—
—
—
165
30.99
Working Capital Days
−3
5.67
−2,723
—
−5,986
−2,112
−6,334
—
—
—
874
588
ROCE %
−6.01%
−7.45%
−52.63%
—
—
—
—
—
—
—
−0.96%
2.96%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Venmax Drugs & Pharmaceuticals insights

56 extracted metrics across FY10–FY27.

Shareholding Pattern

As of Sep 2026

  • Public 75.66%
  • Others 13.87%
  • Promoters 10.46%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Documents

Frequently Asked Questions about Venmax Drugs & Pharmaceuticals

What does Venmax Drugs & Pharmaceuticals Ltd do?
Incorporated in 1998, Venmax Drugs & Pharmaceuticals Ltd is engaged in the business of IT & ITES services
Where is Venmax Drugs & Pharmaceuticals Ltd (VENMAX) listed?
Venmax Drugs & Pharmaceuticals Ltd trades under code 531015 on the BSE.
Which sector does Venmax Drugs & Pharmaceuticals Ltd belong to?
Venmax Drugs & Pharmaceuticals Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Venmax Drugs & Pharmaceuticals Ltd?
Venmax Drugs & Pharmaceuticals Ltd trades at a PE ratio of 57.12 as of 4 Nov 2026, on earnings per share of ₹0.25, against a book value of ₹14.37 per share.
What is the 52-week high and low of Venmax Drugs & Pharmaceuticals Ltd?
Over the last 52 weeks Venmax Drugs & Pharmaceuticals Ltd has traded between ₹12.51 and ₹31.49 as of 4 Nov 2026.
What is the Return on Equity (ROE) of Venmax Drugs & Pharmaceuticals Ltd?
Venmax Drugs & Pharmaceuticals Ltd reported a return on equity of 2.70%. Its debt-to-equity ratio is 0.02.

Company Information

Incorporated in 1998, Venmax Drugs & Pharmaceuticals Ltd is engaged in the business of IT & ITES services

Website venmaxdrugs.com
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/531015.md for Venmax Drugs & Pharmaceuticals Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month